As Novartis expands its CDMO business, it says it is also “in discussions” to further boost its client list amid current “disruptive moments” in the manufacturing industry. Once the pharma giant stabilizes manufacturing for its radiopharmaceuticals like Pluvicto, it will also look into becoming a third-party producer for other radiopharma companies. “It’s very dynamic … … Continue reading Novartis’ CDMO arm eyes growth, scope to welcome competitors’ clients